公开(公告)号：US20190298715A1

公开(公告)日：2019-10-03

申请号：US16338085

申请日：2017-09-29

Applicant: Gregory Motz ,  Konstantinos John Mavrakias ,  Jinbiao Liu ,  Lei Liu ,  Qiangang Zheng ,  Guoliang Xun ,  Qitao Xiao ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Motz ,  Konstantinos John Mavrakias ,  Jinbiao Liu ,  Lei Liu ,  Qiangang Zheng ,  Guoliang Xun ,  Qitao Xiao

IPC: A61K31/496 ,  A61K31/444 ,  C12N15/113 ,  A61K31/404 ,  A61K35/17

Abstract: Provided herein is the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.

公开(公告)号：US10604502B2

公开(公告)日：2020-03-31

申请号：US16012468

申请日：2018-06-19

Applicant: Novartis AG

Inventor： Lei Du-Cuny ,  Qitao Xiao ,  Guoliang Xun ,  Qiangang Zheng

IPC: C07D401/04 ,  A61P35/00 ,  A61P35/02 ,  C07D209/14 ,  C07D409/14 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D498/04 ,  A61K31/4439 ,  A61K31/404 ,  A61K31/4709 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/5383 ,  C07D403/04

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, and R5 are as defined herein.

公开(公告)号：US11420970B1

公开(公告)日：2022-08-23

申请号：US17327226

申请日：2021-05-21

Applicant: NOVARTIS AG

Inventor： Haibing Deng ,  Jinbiao Liu ,  Counde Oyang ,  Ce Wang ,  Qitao Xiao ,  Guoliang Xun ,  Haiqiang Zeng

IPC: C07D473/34

Abstract: The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).

公开(公告)号：US10590079B2

公开(公告)日：2020-03-17

申请号：US16081543

申请日：2017-02-28

Applicant: Novartis AG

Inventor： Lei Du-Cuny ,  Feng He ,  Qitao Xiao ,  Guoliang Xun ,  Qiangang Zheng

IPC: A61K31/404 ,  C07D209/42 ,  C07D209/14 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D405/04 ,  C07D405/06 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/506 ,  A61K45/06

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, R5, and R6 are as defined herein.

公开(公告)号：US20190000880A1

公开(公告)日：2019-01-03

申请号：US16066855

申请日：2016-12-30

Applicant: Gregory Motz ,  Konstantinos John Mavrakias ,  Jinbiao Liu ,  Lei Liu ,  Qiangang Zheng ,  Guoliang Xun ,  Qitao Xiao ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Motz ,  Konstantinos John Mavrakias ,  Jinbiao Liu ,  Lei Liu ,  Qiangang Zheng ,  Guoliang Xun ,  Qitao Xiao

IPC: A61K35/17 ,  C07D207/34 ,  C12N5/0783 ,  C07D401/14 ,  C12N15/113 ,  A61P35/00 ,  C07K16/28 ,  C07K16/24 ,  C07K16/30

Abstract: Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.